Last reviewed · How we verify

Opioid administration morphine

KK Women's and Children's Hospital · Phase 3 active Small molecule

Morphine binds to opioid receptors in the central and peripheral nervous system to reduce pain perception and modulate emotional responses to pain.

Morphine binds to opioid receptors in the central and peripheral nervous system to reduce pain perception and modulate emotional responses to pain. Used for Moderate to severe acute pain, Moderate to severe chronic pain, Postoperative pain.

At a glance

Generic nameOpioid administration morphine
SponsorKK Women's and Children's Hospital
Drug classOpioid agonist
TargetMu-opioid receptor (μ-OR)
ModalitySmall molecule
Therapeutic areaPain management
PhasePhase 3

Mechanism of action

Morphine is a mu-opioid receptor agonist that crosses the blood-brain barrier and acts on opioid receptors in the brain, spinal cord, and peripheral tissues. This binding inhibits the transmission of pain signals and produces analgesia, sedation, and euphoria. It is commonly used for moderate to severe acute and chronic pain management.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: